Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Mar 18, 2023 2:46pm
434 Views
Post# 35346941

New Presentation ...

New Presentation ...- Upcoming milestones are identified for OTENA - acute
- Notice the asteriks on 352 in the pipeline (also being validated for OTENA)
- Robust sales potential is being presented in a very obscure way, in a present dollar amount for peak sales, for USA only, and mostly for post-op (and that's the only way you'd see a number close to $1 BB).  No other way to explain it when we're talking 50% adoption rate for post-op.  No problem, they are trying to advertise to a minimum and that's fine for me.
- Patent protected to 2043
- Trademark application for 2 brand names  - That's LEMBAYLI and GOPIVEO for the USA and globally - trademarks registered on December 1, 2021.

- One additional trademark called SULREVIQ but they are not talking about it.  Likely only for Canada or maybe they scrapped it.  Note, it was registered in Canada on June 9, 2021.

<< Previous
Bullboard Posts
Next >>